Mogamulizumab (Poteligeo) — Clinical FAQs

Question 1

What is Mogamulizumab FDA-approved to treat?

Accepted Answer

Mogamulizumab is FDA-approved for the following oncology indications: 1. Relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after ≥1 prior systemic therapy in adults (August 2018; MAVORIC trial).

Question 2

How does Mogamulizumab work (mechanism of action)?

Accepted Answer

Mogamulizumab is a humanized, defucosylated anti-CCR4 (CC chemokine receptor 4) IgG1 monoclonal antibody. CCR4 is a G protein-coupled chemokine receptor overexpressed on malignant T cells in mycosis fungoides (MF) and Sézary syndrome (SS), as well as on regulatory T cells (Tregs). Defucosylation of the Fc region markedly enhances binding affinity for FcγRIIIa on NK cells and macrophages, substantially augmenting antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) compared with fucosylated antibodies. Depletion of CCR4+ tumor cells and Tregs may also relieve immunosuppression within the tumor microenvironment, potentially restoring antitumor immune responses.

Question 3

How is Mogamulizumab administered?

Accepted Answer

Mogamulizumab is administered Intravenous (IV). Administered as an IV infusion over 60 minutes.

Question 4

What are the most common side effects of Mogamulizumab?

Accepted Answer

The most commonly reported side effects of Mogamulizumab (≥10% incidence) include: Infusion-related reactions (~33%), Rash or drug eruption (~24%), Fatigue (~24%), Diarrhea (~23%), Musculoskeletal pain (~20%) and others (12 total). Consult your oncologist for complete prescribing information.

Question 5

Does Mogamulizumab have a black box warning?

Accepted Answer

Yes. Mogamulizumab carries FDA black box warning(s) regarding: 1. Serious dermatologic reactions including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS): fatal cases reported; discontinue mogamulizumab permanently if SJS, TEN, or DRESS is confirmed or suspected

Question 6

Is Mogamulizumab safe during pregnancy?

Accepted Answer

Mogamulizumab pregnancy safety: No adequate human data in pregnant women. Based on mechanism of action (immune effector depletion including Tregs) and class effects of IgG1 antibodies crossing the placenta, mogamulizumab may cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for 3 months after the last dose. Breastfeeding is not recommended during treatment and for 3 months after the last dose due to potential for serious adverse reactions in the breastfed infant.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

mogamulizumab — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms